Establishment and characterization of a docetaxel‑resistant human prostate cancer cell line
The aim of the present study was to establish a novel docetaxel-resistant prostate cancer cell line and investigate its biological characteristics. The human prostate cell line, PC-3, was exposed to docetaxel, the concentrations of which were increased in a stepwise manner in the medium to select th...
Gespeichert in:
| Veröffentlicht in: | Oncology letters 2020-11, Vol.20 (5), p.1-1 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1 |
|---|---|
| container_issue | 5 |
| container_start_page | 1 |
| container_title | Oncology letters |
| container_volume | 20 |
| creator | Liu, Jian Huang, Yujie Zhu, Danyan Dai, Yao Liu, Dan Zhai, You Liang, Xingguang Wu, Lihua Zhao, Qingwei |
| description | The aim of the present study was to establish a novel docetaxel-resistant prostate cancer cell line and investigate its biological characteristics. The human prostate cell line, PC-3, was exposed to docetaxel, the concentrations of which were increased in a stepwise manner in the medium to select the drug-resistant cell line, PC-3/DTX. The morphological features were observed using inverted microscopy. The growth curves of PC-3 and PC-3/DTX cells were drawn to calculate the doubling time. Flow cytometry was performed to determine cell-cycle distribution. A 3-(4,5-dimethyl-2-thiazol)-2,5-diphenyl-2H tetrazolium bromide assay was performed to test the drug resistance of PC-3 and PC-3/DTX cells. Western blot analysis was conducted to determine the protein expression levels of the mammalian target of rapamycin (mTOR) signaling pathway, which may serve a role in regulating drug resistance in the two cell lines. PC-3/DTX cells exhibited changes in morphology, proliferation rate, doubling time and cell-cycle distributions, compared with PC-3 cells. PC-3/DTX cells were 10.9-fold resistant to docetaxel in comparison with PC-3 cells. The results showed that PC-3/DTX cells overexpressed Rictor and p-AKT(S473) proteins, which are specific subunits or downstream substrates of mTORC2. The new findings suggested that the mTORC2 signaling pathway may serve an important role in the regulation of docetaxel drug resistance of PC-3 cells. In conclusion, PC-3/DTX cells may be applied to study the resistance of anticancer drugs and to identify methods to overcome resistance. Key words: prostate cancer, docetaxel, drug resistance, mTOR, PC-3/DTX |
| doi_str_mv | 10.3892/ol.2020.12093 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7499980</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A638862818</galeid><sourcerecordid>A638862818</sourcerecordid><originalsourceid>FETCH-LOGICAL-c490t-9348aabf87c81f2fffd044bad66f8aaf3304091569a11e8ff1c924cca2418103</originalsourceid><addsrcrecordid>eNptks9vFSEQx4nR2Kb26H0TE-Nln8DyduFi0jT1R9LES6-GzGOHLg0LT2CN9eS_4L_oXyJrm-ozwoGB-cwXhhlCnjO66aTir6PfcMrphnGqukfkmA2Kt4xK_vjBHsQROc35htax7ZmU_VNy1HHVS7Hlx-TTRS6w8y5PM4bSQBgbM0ECUzC5b1BcDE20DTRjNFjgK_qf338kzK6GVX5aZgjNPsW6LdgYCAZTY9D7xruAz8gTCz7j6f16Qq7eXlydv28vP777cH522RqhaGlVJyTAzsrBSGa5tXakQuxg7HtbHbbrqKCKbXsFjKG0lhnFhTHABZOMdifkzZ3sftnNOJqaSQKv98nNkG51BKcPPcFN-jp-0YNQSslV4NW9QIqfF8xFzy6vWUDAuGTNhdiqob5BVvTFP-hNXFKo2a3UICkb-uEPdQ0etQs21nvNKqrP-q4WgUu2am3-Q9U54uxMDGhdPT8IePlXwITgy5SjX9Yy5UOwvQNNLU1OaB8-g1G9to6OXq-to3-3TvcL0zW1aw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2447801767</pqid></control><display><type>article</type><title>Establishment and characterization of a docetaxel‑resistant human prostate cancer cell line</title><source>Spandidos Publications Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Liu, Jian ; Huang, Yujie ; Zhu, Danyan ; Dai, Yao ; Liu, Dan ; Zhai, You ; Liang, Xingguang ; Wu, Lihua ; Zhao, Qingwei</creator><creatorcontrib>Liu, Jian ; Huang, Yujie ; Zhu, Danyan ; Dai, Yao ; Liu, Dan ; Zhai, You ; Liang, Xingguang ; Wu, Lihua ; Zhao, Qingwei</creatorcontrib><description>The aim of the present study was to establish a novel docetaxel-resistant prostate cancer cell line and investigate its biological characteristics. The human prostate cell line, PC-3, was exposed to docetaxel, the concentrations of which were increased in a stepwise manner in the medium to select the drug-resistant cell line, PC-3/DTX. The morphological features were observed using inverted microscopy. The growth curves of PC-3 and PC-3/DTX cells were drawn to calculate the doubling time. Flow cytometry was performed to determine cell-cycle distribution. A 3-(4,5-dimethyl-2-thiazol)-2,5-diphenyl-2H tetrazolium bromide assay was performed to test the drug resistance of PC-3 and PC-3/DTX cells. Western blot analysis was conducted to determine the protein expression levels of the mammalian target of rapamycin (mTOR) signaling pathway, which may serve a role in regulating drug resistance in the two cell lines. PC-3/DTX cells exhibited changes in morphology, proliferation rate, doubling time and cell-cycle distributions, compared with PC-3 cells. PC-3/DTX cells were 10.9-fold resistant to docetaxel in comparison with PC-3 cells. The results showed that PC-3/DTX cells overexpressed Rictor and p-AKT(S473) proteins, which are specific subunits or downstream substrates of mTORC2. The new findings suggested that the mTORC2 signaling pathway may serve an important role in the regulation of docetaxel drug resistance of PC-3 cells. In conclusion, PC-3/DTX cells may be applied to study the resistance of anticancer drugs and to identify methods to overcome resistance. Key words: prostate cancer, docetaxel, drug resistance, mTOR, PC-3/DTX</description><identifier>ISSN: 1792-1074</identifier><identifier>EISSN: 1792-1082</identifier><identifier>DOI: 10.3892/ol.2020.12093</identifier><identifier>PMID: 32968452</identifier><language>eng</language><publisher>Athens: Spandidos Publications</publisher><subject>Analysis ; Aprotinin ; Biotechnology ; Biphenyl (Compound) ; Cancer therapies ; Cell cycle ; Cell growth ; Drug resistance ; EDTA ; Kinases ; Mortality ; Penicillin ; Prostate cancer ; Scientific equipment industry</subject><ispartof>Oncology letters, 2020-11, Vol.20 (5), p.1-1</ispartof><rights>COPYRIGHT 2020 Spandidos Publications</rights><rights>Copyright Spandidos Publications UK Ltd. 2020</rights><rights>Copyright: © Liu et al. 2020</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c490t-9348aabf87c81f2fffd044bad66f8aaf3304091569a11e8ff1c924cca2418103</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7499980/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7499980/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids></links><search><creatorcontrib>Liu, Jian</creatorcontrib><creatorcontrib>Huang, Yujie</creatorcontrib><creatorcontrib>Zhu, Danyan</creatorcontrib><creatorcontrib>Dai, Yao</creatorcontrib><creatorcontrib>Liu, Dan</creatorcontrib><creatorcontrib>Zhai, You</creatorcontrib><creatorcontrib>Liang, Xingguang</creatorcontrib><creatorcontrib>Wu, Lihua</creatorcontrib><creatorcontrib>Zhao, Qingwei</creatorcontrib><title>Establishment and characterization of a docetaxel‑resistant human prostate cancer cell line</title><title>Oncology letters</title><description>The aim of the present study was to establish a novel docetaxel-resistant prostate cancer cell line and investigate its biological characteristics. The human prostate cell line, PC-3, was exposed to docetaxel, the concentrations of which were increased in a stepwise manner in the medium to select the drug-resistant cell line, PC-3/DTX. The morphological features were observed using inverted microscopy. The growth curves of PC-3 and PC-3/DTX cells were drawn to calculate the doubling time. Flow cytometry was performed to determine cell-cycle distribution. A 3-(4,5-dimethyl-2-thiazol)-2,5-diphenyl-2H tetrazolium bromide assay was performed to test the drug resistance of PC-3 and PC-3/DTX cells. Western blot analysis was conducted to determine the protein expression levels of the mammalian target of rapamycin (mTOR) signaling pathway, which may serve a role in regulating drug resistance in the two cell lines. PC-3/DTX cells exhibited changes in morphology, proliferation rate, doubling time and cell-cycle distributions, compared with PC-3 cells. PC-3/DTX cells were 10.9-fold resistant to docetaxel in comparison with PC-3 cells. The results showed that PC-3/DTX cells overexpressed Rictor and p-AKT(S473) proteins, which are specific subunits or downstream substrates of mTORC2. The new findings suggested that the mTORC2 signaling pathway may serve an important role in the regulation of docetaxel drug resistance of PC-3 cells. In conclusion, PC-3/DTX cells may be applied to study the resistance of anticancer drugs and to identify methods to overcome resistance. Key words: prostate cancer, docetaxel, drug resistance, mTOR, PC-3/DTX</description><subject>Analysis</subject><subject>Aprotinin</subject><subject>Biotechnology</subject><subject>Biphenyl (Compound)</subject><subject>Cancer therapies</subject><subject>Cell cycle</subject><subject>Cell growth</subject><subject>Drug resistance</subject><subject>EDTA</subject><subject>Kinases</subject><subject>Mortality</subject><subject>Penicillin</subject><subject>Prostate cancer</subject><subject>Scientific equipment industry</subject><issn>1792-1074</issn><issn>1792-1082</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNptks9vFSEQx4nR2Kb26H0TE-Nln8DyduFi0jT1R9LES6-GzGOHLg0LT2CN9eS_4L_oXyJrm-ozwoGB-cwXhhlCnjO66aTir6PfcMrphnGqukfkmA2Kt4xK_vjBHsQROc35htax7ZmU_VNy1HHVS7Hlx-TTRS6w8y5PM4bSQBgbM0ECUzC5b1BcDE20DTRjNFjgK_qf338kzK6GVX5aZgjNPsW6LdgYCAZTY9D7xruAz8gTCz7j6f16Qq7eXlydv28vP777cH522RqhaGlVJyTAzsrBSGa5tXakQuxg7HtbHbbrqKCKbXsFjKG0lhnFhTHABZOMdifkzZ3sftnNOJqaSQKv98nNkG51BKcPPcFN-jp-0YNQSslV4NW9QIqfF8xFzy6vWUDAuGTNhdiqob5BVvTFP-hNXFKo2a3UICkb-uEPdQ0etQs21nvNKqrP-q4WgUu2am3-Q9U54uxMDGhdPT8IePlXwITgy5SjX9Yy5UOwvQNNLU1OaB8-g1G9to6OXq-to3-3TvcL0zW1aw</recordid><startdate>20201101</startdate><enddate>20201101</enddate><creator>Liu, Jian</creator><creator>Huang, Yujie</creator><creator>Zhu, Danyan</creator><creator>Dai, Yao</creator><creator>Liu, Dan</creator><creator>Zhai, You</creator><creator>Liang, Xingguang</creator><creator>Wu, Lihua</creator><creator>Zhao, Qingwei</creator><general>Spandidos Publications</general><general>Spandidos Publications UK Ltd</general><general>D.A. Spandidos</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20201101</creationdate><title>Establishment and characterization of a docetaxel‑resistant human prostate cancer cell line</title><author>Liu, Jian ; Huang, Yujie ; Zhu, Danyan ; Dai, Yao ; Liu, Dan ; Zhai, You ; Liang, Xingguang ; Wu, Lihua ; Zhao, Qingwei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c490t-9348aabf87c81f2fffd044bad66f8aaf3304091569a11e8ff1c924cca2418103</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Analysis</topic><topic>Aprotinin</topic><topic>Biotechnology</topic><topic>Biphenyl (Compound)</topic><topic>Cancer therapies</topic><topic>Cell cycle</topic><topic>Cell growth</topic><topic>Drug resistance</topic><topic>EDTA</topic><topic>Kinases</topic><topic>Mortality</topic><topic>Penicillin</topic><topic>Prostate cancer</topic><topic>Scientific equipment industry</topic><toplevel>online_resources</toplevel><creatorcontrib>Liu, Jian</creatorcontrib><creatorcontrib>Huang, Yujie</creatorcontrib><creatorcontrib>Zhu, Danyan</creatorcontrib><creatorcontrib>Dai, Yao</creatorcontrib><creatorcontrib>Liu, Dan</creatorcontrib><creatorcontrib>Zhai, You</creatorcontrib><creatorcontrib>Liang, Xingguang</creatorcontrib><creatorcontrib>Wu, Lihua</creatorcontrib><creatorcontrib>Zhao, Qingwei</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oncology letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Liu, Jian</au><au>Huang, Yujie</au><au>Zhu, Danyan</au><au>Dai, Yao</au><au>Liu, Dan</au><au>Zhai, You</au><au>Liang, Xingguang</au><au>Wu, Lihua</au><au>Zhao, Qingwei</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Establishment and characterization of a docetaxel‑resistant human prostate cancer cell line</atitle><jtitle>Oncology letters</jtitle><date>2020-11-01</date><risdate>2020</risdate><volume>20</volume><issue>5</issue><spage>1</spage><epage>1</epage><pages>1-1</pages><issn>1792-1074</issn><eissn>1792-1082</eissn><abstract>The aim of the present study was to establish a novel docetaxel-resistant prostate cancer cell line and investigate its biological characteristics. The human prostate cell line, PC-3, was exposed to docetaxel, the concentrations of which were increased in a stepwise manner in the medium to select the drug-resistant cell line, PC-3/DTX. The morphological features were observed using inverted microscopy. The growth curves of PC-3 and PC-3/DTX cells were drawn to calculate the doubling time. Flow cytometry was performed to determine cell-cycle distribution. A 3-(4,5-dimethyl-2-thiazol)-2,5-diphenyl-2H tetrazolium bromide assay was performed to test the drug resistance of PC-3 and PC-3/DTX cells. Western blot analysis was conducted to determine the protein expression levels of the mammalian target of rapamycin (mTOR) signaling pathway, which may serve a role in regulating drug resistance in the two cell lines. PC-3/DTX cells exhibited changes in morphology, proliferation rate, doubling time and cell-cycle distributions, compared with PC-3 cells. PC-3/DTX cells were 10.9-fold resistant to docetaxel in comparison with PC-3 cells. The results showed that PC-3/DTX cells overexpressed Rictor and p-AKT(S473) proteins, which are specific subunits or downstream substrates of mTORC2. The new findings suggested that the mTORC2 signaling pathway may serve an important role in the regulation of docetaxel drug resistance of PC-3 cells. In conclusion, PC-3/DTX cells may be applied to study the resistance of anticancer drugs and to identify methods to overcome resistance. Key words: prostate cancer, docetaxel, drug resistance, mTOR, PC-3/DTX</abstract><cop>Athens</cop><pub>Spandidos Publications</pub><pmid>32968452</pmid><doi>10.3892/ol.2020.12093</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1792-1074 |
| ispartof | Oncology letters, 2020-11, Vol.20 (5), p.1-1 |
| issn | 1792-1074 1792-1082 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7499980 |
| source | Spandidos Publications Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Analysis Aprotinin Biotechnology Biphenyl (Compound) Cancer therapies Cell cycle Cell growth Drug resistance EDTA Kinases Mortality Penicillin Prostate cancer Scientific equipment industry |
| title | Establishment and characterization of a docetaxel‑resistant human prostate cancer cell line |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T03%3A34%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Establishment%20and%20characterization%20of%20a%20docetaxel%E2%80%91resistant%20human%20prostate%20cancer%20cell%20line&rft.jtitle=Oncology%20letters&rft.au=Liu,%20Jian&rft.date=2020-11-01&rft.volume=20&rft.issue=5&rft.spage=1&rft.epage=1&rft.pages=1-1&rft.issn=1792-1074&rft.eissn=1792-1082&rft_id=info:doi/10.3892/ol.2020.12093&rft_dat=%3Cgale_pubme%3EA638862818%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2447801767&rft_id=info:pmid/32968452&rft_galeid=A638862818&rfr_iscdi=true |